Find Novel Drugs for Infections and Infectious Diseases under Discovery

Lead Product(s): 2G-Dabocins

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Novo Holdings

Deal Size: $11.9 million Upfront Cash: Undisclosed

Deal Type: Investment January 06, 2020

Details:

This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.